Evommune, Inc.

Evommune is a clinical-stage biotechnology company developing innovative therapies for chronic inflammatory diseases. The company's initial clinical development programs focus on chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). Evommune aims to improve patients' daily lives and prevent long-term effects of uncontrolled inflammation by advancing a portfolio of differentiated product candidates. The company identifies and advances potent, highly selective molecules with distinctive mechanisms of action. Evommune currently has two product candidates, EVO756 and EVO301, in Phase 2 development. EVO756 is initially being developed for the treatment of CSU and AD, while EVO301 is being developed for the treatment of AD and UC. Evommune sees broad expansion potential for both programs across additional chronic inflammatory diseases and intends to advance additional preclinical programs into clinical development. The most advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons. Dysregulated MRGPRX2 activity can play a key role in the pathogenesis of a multitude of systemic chronic inflammatory diseases.